Viktoria Moschetti
Ingelheim Am Rhein, RP, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF).
Journal: Expert opinion on biological therapy
Published: May 13, 2024
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: March 09, 2021
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
Journal: Clinical drug investigation
Published: May 31, 2018
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: March 15, 2018
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies.
Journal: Clinical and translational science
Published: December 05, 2017
Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.
Journal: European journal of drug metabolism and pharmacokinetics
Published: October 28, 2017
The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Published: July 13, 2017
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Journal: British journal of clinical pharmacology
Published: July 29, 2016
A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers.
Journal: Human psychopharmacology
Published: July 14, 2016
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Journal: Clinical pharmacokinetics
Published: June 19, 2016
Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers.
Journal: Thrombosis and haemostasis
Published: May 19, 2016
Last Updated: 09/26/2026